rs12721629 — CYP3A4 *16B

Missense variant causing substrate-dependent reduced CYP3A4 activity, most prevalent in Japanese and East Asian populations

See your personal result for CYP3A4

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CYP3A4*16B — A Rare East Asian Variant Altering Drug Metabolism in a Substrate-Dependent Way

CYP3A4 is the most abundant drug-metabolizing enzyme in the human liver, responsible for the biotransformation of approximately 50% of all clinically used medications11 50% of all clinically used medications
Including statins, immunosuppressants, calcium channel blockers, benzodiazepines, chemotherapy agents, and many antibiotics. The CYP3A4*16B haplotype, defined primarily by the rs12721629 variant, carries a missense substitution (Thr185Ser in older literature numbering; p.Leu373Val in current HGVS notation using transcript NM_017460.6) that alters the enzyme's active site geometry in a way that affects different drug substrates to different degrees.

This variant is largely confined to Japanese and broader East Asian populations, where heterozygous carriers appear in roughly 3-4% of individuals. In European, African, and South Asian populations it is essentially absent. The CYP3A4 gene itself sits on the minus strand of chromosome 7, so the coding-strand change (c.554C>G in older transcript notation, c.1117C>G in NM_017460.6) is reported on the plus strand as G>C at chromosomal position 99,762,177 (GRCh38).

The Mechanism

The Thr185Ser substitution (threonine-to-serine at position 185 in the older protein numbering) changes a hydroxyl-bearing residue in the substrate-binding channel of CYP3A4. In vitro studies using recombinant enzyme22 In vitro studies using recombinant enzyme
CYP3A4*16 expressed in Sf21 insect cells co-expressing human NADPH-P450 reductase revealed that the effect is strikingly substrate-dependent: intrinsic clearance of midazolam (a standard CYP3A4 probe) fell by about 50% for the primary 1'-hydroxylation pathway and 30% for 4-hydroxylation, while carbamazepine epoxidation dropped by 74%. This contrast with, for example, CYP3A4*22, which reduces enzyme expression uniformly across substrates, suggests the *16B substitution changes the substrate access channel geometry rather than overall protein stability or expression.

The kinetic mechanism differs by substrate. For midazolam, the variant shows elevated Km (reduced binding affinity) with lower Vmax. For carbamazepine, the changes are more complex and consistent with a distorted two-site cooperative binding model, suggesting the variant may disrupt allosteric activation normally seen with this substrate.

The Evidence

The most clinically informative data comes from two studies in Japanese cancer patients. Sai et al. examined 235 patients33 Sai et al. examined 235 patients
paclitaxel pharmacokinetics measured in 229 with usable plasma samples receiving paclitaxel chemotherapy and identified eight *16B carriers (all heterozygotes). Carriers showed a 20% lower median AUC ratio for the 3'-p-hydroxylation metabolite and a 2.4-fold higher ratio for the 6α-hydroxylation product (P<0.001), indicating that CYP3A4*16B shifts paclitaxel metabolism away from the 3'-p-hydroxylation route toward the 6α-hydroxylation route — with potential consequences for drug efficacy and metabolite toxicity profiles.

Sai et al. studied 177 Japanese cancer patients44 Sai et al. studied 177 Japanese cancer patients
Irinotecan pharmacokinetics with CYP3A4 haplotype analysis receiving irinotecan and found that male patients carrying *16B had approximately 50% lower APC/irinotecan ratios, indicating significantly reduced CYP3A4-mediated oxidative metabolism of this anticancer drug. No female *16B carriers were enrolled. Although overall irinotecan total clearance was not significantly different between genotypes — suggesting compensatory pathways — the altered metabolite ratios could affect the balance between efficacy and toxicity (the APC pathway is thought to be a detoxification route).

Maekawa et al.55 Maekawa et al.
Kinetic characterization of CYP3A4.16 in insect cell microsomes provided the mechanistic foundation: recombinant CYP3A4*16 shows 50% reduced intrinsic clearance for midazolam 1'-hydroxylation, 30% for midazolam 4-hydroxylation, and 74% for carbamazepine 10,11-epoxide formation, confirming that the magnitude of impairment varies considerably by substrate.

CYP3A4*16B is not included in current CPIC or DPWG clinical guidelines, which focus on CYP3A4*22 (rs35599367) and the CYP3A5 *1/*3 system (rs776746) as the established pharmacogenomic variants for CYP3A4 pathway guidance. The rarity of *16B outside East Asian populations limits the evidence base for formal guideline development.

Practical Actions

Because CYP3A4*16B is heterozygous in virtually all carriers and causes moderate, substrate-dependent activity reduction, the clinical impact depends heavily on which drugs you take. For chemotherapy drugs like paclitaxel and irinotecan, the altered metabolite ratios could affect both efficacy and the toxicity profile — oncologists should be aware that standard dosing may produce different metabolite distributions in *16B carriers. For drugs with narrow therapeutic windows (carbamazepine, tacrolimus), the 50-74% reduction in intrinsic clearance observed in vitro suggests that doses appropriate for normal CYP3A4 metabolizers may need adjustment.

The absence of CYP3A4*16B from clinical pharmacogenomic panels used in Western countries means carriers are unlikely to receive a pharmacogenomic alert for this specific variant. East Asian patients undergoing comprehensive pharmacogenomic testing may benefit from inclusion of this variant.

Interactions

CYP3A4*16B's effects are additive with other reduced-function CYP3A variants. Individuals of East Asian ancestry who carry both CYP3A4*16B and CYP3A5*3/*3 (rs776746 CC, the most common genotype globally) would have reduced function in both CYP3A enzymes, potentially reaching total CYP3A activity levels comparable to carriers of CYP3A4*22 in European populations.

The substrate-dependent nature of *16B also means that drug-drug interactions can produce unpredictable results. A CYP3A4 inhibitor like itraconazole that uniformly blocks enzyme activity may have a larger relative impact on carbamazepine (already 74% reduced) than on midazolam (50% reduced) in *16B carriers, since both baseline activities start from a lower point. Conversely, inducers like rifampin may partially rescue activity in *16B by upregulating enzyme expression to compensate for per-molecule inefficiency.

The CYP3A4*22 variant (rs35599367) is a separate, more common, and better-studied reduced-function allele that should be tested alongside *16B in East Asian patients receiving narrow therapeutic index CYP3A4 substrates.

Drug Interactions

paclitaxel reduced_efficacy literature
irinotecan reduced_efficacy literature
midazolam dose_adjustment literature
carbamazepine dose_adjustment literature
tacrolimus dose_adjustment literature
simvastatin dose_adjustment literature
atorvastatin dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal Metabolizer Normal

Standard CYP3A4 enzyme activity — typical metabolism of paclitaxel, carbamazepine, and other CYP3A4 substrates

You carry two copies of the reference allele at rs12721629, the wild-type CYP3A4*1 haplotype at this position. Your CYP3A4 enzyme activity for this variant is unaffected. This genotype is found in essentially all individuals of European, African, and South Asian ancestry, and in about 96% of East Asians. Your metabolism of CYP3A4-substrate drugs — statins, chemotherapy agents, immunosuppressants, benzodiazepines, and calcium channel blockers — is governed by other genetic and environmental factors, not this variant.

CG Intermediate Metabolizer Intermediate

One copy of CYP3A4*16B — substrate-dependent reduction in enzyme activity, most relevant for paclitaxel, irinotecan, and carbamazepine

The CYP3A4*16B missense substitution changes an amino acid (Thr185Ser) in the enzyme's substrate-binding channel, altering the geometry available to different drug molecules. The consequence is substrate-dependent: the in vitro intrinsic clearance reduction ranges from 30% (midazolam 4-hydroxylation) to 74% (carbamazepine epoxidation), with the paclitaxel studies showing a qualitative shift in metabolic routing rather than simple reduced total metabolism.

As a heterozygote, your total CYP3A4 enzyme pool includes both wild-type and *16B copies. The net effect at the whole-body level is an intermediate phenotype — generally less pronounced than the homozygous state but potentially clinically meaningful for drugs with steep dose-response curves or narrow therapeutic windows.

This variant is not included in Western pharmacogenomic panels (CPIC, DPWG), which means you are unlikely to receive a routine clinical pharmacogenomic alert for it. East Asian-optimized testing panels may include it.

CC Poor Metabolizer Poor

Two copies of CYP3A4*16B — significantly reduced enzyme activity across multiple drug substrates

The homozygous *16B/*16B state has not been directly studied in clinical pharmacokinetic trials due to its extreme rarity. Extrapolating from heterozygous data and in vitro recombinant enzyme kinetics, the homozygous genotype would be expected to produce the most pronounced reduction in CYP3A4 activity at this locus. Given that both enzyme copies carry the active-site substitution, the impairment cannot be compensated from the wild-type allele (as in heterozygotes).

However, it is important to note that CYP3A4*16B impairs enzyme efficiency rather than abolishing it. Even for carbamazepine — the most affected substrate tested — residual intrinsic clearance of 26% of wild-type remains in vitro. This is different from a null allele (like TPMT*3A or some CYP2C19*2 homozygotes) where function is fully absent.

The clinical implications are similar to heterozygotes but amplified. Drugs metabolized primarily via the CYP3A4 pathways most affected by this substitution (carbamazepine, midazolam, paclitaxel) will achieve higher plasma levels than expected at standard doses. Therapeutic drug monitoring and conservative initial dosing are strongly indicated.